Colin Hill is Chairman and CEO of Gene Network Sciences. In this role, Hill develops the strategic roadmap and vision for the company and oversees the leadership of business operations. Hill brings years of hands-on scientific experience to his role, with expertise in the areas of computational physics and systems biology. Colin Hill was recently named to MIT Technology Review's TR100 list of the top innovators in the world under the age of 35, and was also selected by Black Enterprise as the winner of the 2004 "Rising Star" small business award. Colin Hill graduated from Virginia Tech with a degree in physics and went on to earn masters degrees in physics from McGill and Cornell Universities.
So what I'm going to talk to you about tonight is a company called Gene Network Sciences (GNS), it is a real life start up. I am not giving you the talk ten years after the IPO and we have already made billions, we are still in the middle of this and even though we have been operating for over six ...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
Colin Hill States Poor Understanding Of Human Biology Leads To Medical Problems That GNS Is Trying To Solve
Colin Hill States Computer Models Increase Probability For Pharmaceutical Companies To Get New Drugs To Market
Colin Hill Discusses Software Technology That GNS Uses To Simulate And Predict Drug Outcomes
